Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 2 diabetes

• HbA1c greater than 7.0% and/or hypoglycaemia

• variable FBG and/or weight increase

• the selection of the subjects will be at the discretion of the participating physician

Exclusion Criteria:

• non-type 2 diabetes

• current treatment with Levemir® or Insulatard®

• hypersensitivity to Levemir® or Insulatard® or to any of the excipients

• women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months